Illumina Core Illumina — R&D increased by 0.4% to $240.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.8%, from $252.00M to $240.00M. Over 3 years (FY 2022 to FY 2025), Core Illumina — R&D shows relatively stable performance with a -1.2% CAGR.
Higher spending signals a focus on long-term innovation and future growth, whereas significant cuts might indicate a shift toward short-term profitability at the expense of future competitiveness.
Captures the investment in innovation, including the development of new sequencing platforms, software enhancements, and...
Standard R&D expense reported by technology and life science companies.
ilmn_segment_core_illumina_research_and_development| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $251.00M | $251.00M | $251.00M | $251.00M | $257.50M | $257.50M | $257.50M | $257.50M | $241.00M | $241.00M | $253.00M | $256.00M | $252.00M | $247.00M | $229.00M | $239.00M | $240.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +2.6% | +0.0% | +0.0% | +0.0% | -6.4% | +0.0% | +5.0% | +1.2% | -1.6% | -2.0% | -7.3% | +4.4% | +0.4% |
| YoY Change | — | — | — | — | +2.6% | +2.6% | +2.6% | +2.6% | -6.4% | -6.4% | -1.7% | -0.6% | +4.6% | +2.5% | -9.5% | -6.6% | -4.8% |